BURNABY, British Columbia, January 2018
Lungpacer Medical, Inc., announced the completion of enrollment into the RESCUE 1 feasibility study. This novel, first-of-its-kind, FDA-designated breakthrough device delivered temporary transvenous diaphragmatic neurostimulation (TTDN) in a small cohort of patients suffering from failure to wean from MV. All patients were considered to have VIDD at the time of study enrollment. Results from the study are expected to be presented at a major upcoming meeting.